TY - JOUR
T1 - Complement activation in COVID-19 and targeted therapeutic options
T2 - A scoping review
AU - Lim, Endry Hartono Taslim
AU - van Amstel, Rombout Benjamin Ezra
AU - de Boer, Vieve Victoria
AU - van Vught, Lonneke Alette
AU - de Bruin, Sanne
AU - Brouwer, Matthijs Christian
AU - Vlaar, Alexander Petrus Johannes
AU - van de Beek, Diederik
N1 - Funding Information: We thank Faridi van Etten-Jamaludin for her advice and help with the literature search and Esmeralda Lynn Hady for graphic design. Publisher Copyright: © 2022 The Authors
PY - 2022/7/30
Y1 - 2022/7/30
N2 - Increasing evidence suggests that activation of the complement system plays a key role in the pathogenesis and disease severity of Coronavirus disease 2019 (COVID-19). We used a systematic approach to create an overview of complement activation in COVID-19 based on histopathological, preclinical, multiomics, observational and clinical interventional studies. A total of 1801 articles from PubMed, EMBASE and Cochrane was screened of which 157 articles were included in this scoping review. Histopathological, preclinical, multiomics and observational studies showed apparent complement activation through all three complement pathways and a correlation with disease severity and mortality. The complement system was targeted at different levels in COVID-19, of which C5 and C5a inhibition seem most promising. Adequately powered, double blind RCTs are necessary in order to further investigate the effect of targeting the complement system in COVID-19.
AB - Increasing evidence suggests that activation of the complement system plays a key role in the pathogenesis and disease severity of Coronavirus disease 2019 (COVID-19). We used a systematic approach to create an overview of complement activation in COVID-19 based on histopathological, preclinical, multiomics, observational and clinical interventional studies. A total of 1801 articles from PubMed, EMBASE and Cochrane was screened of which 157 articles were included in this scoping review. Histopathological, preclinical, multiomics and observational studies showed apparent complement activation through all three complement pathways and a correlation with disease severity and mortality. The complement system was targeted at different levels in COVID-19, of which C5 and C5a inhibition seem most promising. Adequately powered, double blind RCTs are necessary in order to further investigate the effect of targeting the complement system in COVID-19.
KW - COVID-19
KW - Complement cascade
KW - Complement inhibition
KW - Review
KW - SARS-CoV-2
UR - http://www.scopus.com/inward/record.url?scp=85135518399&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.blre.2022.100995
DO - https://doi.org/10.1016/j.blre.2022.100995
M3 - Review article
C2 - 35934552
SN - 0268-960X
JO - Blood Reviews
JF - Blood Reviews
M1 - 100995
ER -